Brief: Provectus Biopharmaceuticals Announces Oral Presentation Of Updated Study Data From Metastatic Neuroendocrine Cancer Phase 1 Trial Of Pv-10® At 2022 European Neuroendocrine Tumor Society (Enets) Annual Conference
16/03/2022 13:07
March 16 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ORAL PRESENTATION
OF
UPDATED STUDY DATA FROM METASTATIC NEUROENDOCRINE CANCER PHASE 1
TRIAL OF PV-10® AT 2022 EUROPEAN NEUROENDOCRINE TUMOR SOCIETY
(ENETS) ANNUAL CONFERENCE
Source text for Eikon: ID:nGNX6CRlT4
Further company coverage: PVCT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting